This series of bite-sized episodes features essential insights into the diagnosis and management of limb-girdle muscular dystrophy 2I/R9 (LGMD2I/R9), an FKRP-related subtype of LGMD. Drs. John Vissing and Conrad Weihl share expert perspectives on genetics, clinical presentation, diagnostic strategies, patient-centered management, and current as well as emerging therapeutic options. The series also highlights challenges in care delivery, including access to genetic testing and the role of multidisciplinary support.
Establishing Our Foundation of LGMD2I/R9
Bridging Gaps in LGMD Care
Media formats available:
Details
Presenters
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
John Vissing, MD, DMSci
Professor of Neurology
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Dr. Vissing has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Amicus, Argenx BVBA, Biogen, Fulcrum Therapeutics, Regeneron, Roche, Sanofi Genzyme, Sarepta Therapeutics, UCB
Conrad C. Weihl, MD, PhD
Professor, Division of Adult Neurology
Washington University in St. Louis
St. Louis, MO
Dr. Weihl has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Abcuro, ML Bio, Sarepta Therapeutics
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Parul Yadav, MD, has no relevant relationships to disclose.
- Cindy Davidson has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Identify the genetic basis, clinical presentation, and progression of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) to facilitate earlier recognition and diagnosis
- Explain the diagnostic pathway, including key laboratory, imaging, and genetic testing modalities, used to confirm LGMD2I/R9
- Evaluate the impact of LGMD2I/R9 on patients and caregivers, emphasizing the importance of multidisciplinary care and patient advocacy
- Describe current management strategies and emerging therapeutic approaches aimed at improving patient outcomes in LGMD2I/R9
- Identify the genetic basis, clinical presentation, and progression of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) to facilitate earlier recognition and diagnosis
Target Audience
This activity has been designed to meet the educational needs of neurologists and primary care physicians as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with Limb-Girdle Muscular Dystrophy 2I/R9.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-077-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until July 10, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by an independent educational grant from BridgeBio Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of TotalCME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this materialis not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
